首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2077538

正腎上腺素再回收抑制劑（SNRI）市場：依應用、通路和地區分類

Serotonin Norepinephrine Inhibitor Market, By Application, By Distribution Channel, By Region

出版日期: 2026年04月29日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，正腎上腺素再回收抑制劑(SNRI) 市場規模將達到 71.3 億美元，到 2033 年將達到 96.4 億美元。預計 2026 年至 2033 年的複合年成長率為 4.4%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	71.3億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	4.40%	2033年市場規模預測：	96.4億美元

正腎上腺素再回收抑制劑（SNRIs）是一類常用的抗憂鬱症藥物，用於治療重度憂鬱症（MDD）和其他情緒障礙。 SNRIs 的作用機轉是抑制大腦中兩種重要神經傳導物質－血清素和正腎上腺素的再攝取。透過防止這些神經傳導物質被神經元重新吸收，SNRIs 可以提高大腦中血清素和去甲腎上腺素的濃度，從而增強它們的作用。血清素與情緒、情緒和睡眠密切相關。去甲腎上腺素則與清醒和精力有關。提高這些神經傳導物質的水平可以改善腦細胞之間的訊息傳遞，從而對情緒產生積極影響，並對憂鬱症患者有益。

常用的SNRI類藥物包括以下幾種：

文拉法辛（Effexor XR）。
Duloxetine（欣百達）。
Desvenlafaxine（普利司他）。
levomilnacipran（Fetzima）。

SNRIs 也被批准用於治療其他疾病，例如焦慮症、慢性疼痛（包括纖維肌痛）以及與糖尿病相關的神經病變疼痛。

市場動態：

全球憂鬱症患者人數的不斷增加是推動全球正腎上腺素再回收抑制劑（SNRI）市場成長的主要因素。根據世界衛生組織（WHO）統計，全球超過5%的人口患有憂鬱症。由於社會隔離加劇、職場環境壓力增加等多種因素導致憂鬱症的發生，預計這一數字在不久的將來還會進一步上升。此外，人們對有效憂鬱症治療方法的需求不斷成長，也促進了該市場的發展。新冠疫情的爆發導致多個國家失業率上升和經濟不穩定，家庭收入下降，加劇了人們的壓力和焦慮，進而導致對抗抗憂鬱症的需求增加。

另一方面，藥物相關的副作用預計將阻礙全球正腎上腺素再回收抑制劑（SNRI）市場的成長。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數，對全球正腎上腺素再回收抑制劑(SNRI) 市場中的主要公司進行了概況介紹：公司概況、產品系列、主要亮點、財務績效和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球正腎上腺素抑制劑市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球正腎上腺素再回收抑制劑市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

公司簡介
- Pfizer Inc.
- Eli Lilly and Company
- Allergan Plc.
- AstraZeneca Plc.
- Forest Laboratories Inc.
- Johnson & Johnson
- Lundbeck A/S
- Merck & Co., Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Wyeth Pharmaceuticals Inc.
- Zydus Cadila Healthcare Ltd.
分析師意見

第8章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI5718

Serotonin Norepinephrine Inhibitor Market is estimated to be valued at USD 7.13 Bn in 2026 and is expected to reach USD 9.64 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 7.13 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.40%	2033 Value Projection:	USD 9.64 Bn

A Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) is a class of medications typically used as antidepressants in the treatment of major depressive disorder (MDD) and other mood disorders. SNRIs work by inhibiting the reuptake of two important neurotransmitters in the brain - serotonin and norepinephrine. By blocking the reabsorption (reuptake) of these neurotransmitters into the neurons, SNRIs increase the levels and enhance the actions of serotonin and norepinephrine in the brain. Serotonin is involved in mood, emotion, and sleep. Norepinephrine is related to alertness and energy. Increasing the amount of these neurotransmitters improves communication between the brain cells and can have a positive impact on mood and emotion, which is beneficial for patients suffering from depression.

Some commonly prescribed SNRIs include:-

Venlafaxine (Effexor XR)
Duloxetine (Cymbalta)
Desvenlafaxine (Pristiq)
Levomilnacipran (Fetzima)

SNRIs are also approved to treat other conditions such as anxiety disorders, chronic pain conditions like fibromyalgia, and neuropathic pain associated with diabetes.

Market Dynamics:

Rising number of people suffering from depression globally is a major factor driving the market growth of the global serotonin norepinephrine inhibitor market. According to World Health Organization (WHO), over 5.0% of the worldwide population suffers from depression. This number is expected to increase in the near future, due to various factors such as increasing social isolation and stressful work environment, which leads to the development of depression. The increase in the demand for effective treatment of depression is also driving the growth of this market. The emergence of COVID-19 pandemic increased the unemployment rate in several countries and has led to financial instability. This has resulted in a decrease in the household income, which is causing stress and anxiety among people which in turn is increasing the demand for antidepressant drugs.

On the other hand, side effects associated with the drugs is expected to hamper the market growth of the global serotonin norepinephrine inhibitor market.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global serotonin norepinephrine inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Eli Lilly and Company, Allergan Plc., AstraZeneca Plc., Forest Laboratories Inc., Johnson & Johnson, Lundbeck A/S, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wyeth Pharmaceuticals Inc., and Zydus Cadila Healthcare Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global serotonin norepinephrine inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global serotonin norepinephrine inhibitor market

Detailed Segmentation:

Global Serotonin Norepinephrine Inhibitor Market, By Application (Revenue, USD Bn, 2021 - 2033)
Depression
Anxiety Disorders
Chronic Pain
Diabetic Neuropathy
Others
Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Top Companies in the Global Serotonin Norepinephrine Inhibitor Market
Pfizer Inc.
Eli Lilly and Company
Allergan Plc.
AstraZeneca Plc.
Forest Laboratories Inc.
Johnson & Johnson
Lundbeck A/S
Merck & Co., Inc.
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Wyeth Pharmaceuticals Inc.
Zydus Cadila Healthcare Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
  - Increase prevalence of depression and anxiety disorders
  - Availability of new and improved drugs
- Restraints
  - Side effects
- Opportunities
  - Increasing adoption of telemedicine
Key Highlights
Regulatory Scenario
Recent trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions and Collaborations

4. Global Serotonin Norepinephrine Inhibitor Market, By Application, 2021-2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Anxiety Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Chronic Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Diabetic Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

5. Global Serotonin Norepinephrine Inhibitor Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)

6. Global Serotonin Norepinephrine Inhibitor Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, For Sub-region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Sub-region, 2022 - 2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
  - China
  - Japan
  - India
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country 2021 - 2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Company Profile
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Eli Lilly and Company
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Allergan Plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AstraZeneca Plc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Forest Laboratories Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Johnson & Johnson
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Lundbeck A/S
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Otsuka Pharmaceutical Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sun Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Takeda Pharmaceutical Company Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Torrent Pharmaceuticals Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Wyeth Pharmaceuticals Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Zydus Cadila Healthcare Ltd.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
Analysts' Views